EML4-ALK-mediated Activation of the JAK2-STAT Pathway is Critical for Non-small Cell Lung Cancer Transformation

Aberrant expression of EML4-ALK leads to JAK2-STAT signaling pathway activation, an essential part of the development of non-small cell lung cancer. READ ARTICLE

BMC Pulmonary Medicine DOI: https://doi.org/10.1186/s12890-021-01553-z

Authors: Ying Li, Yongwen Li, Hongbing Zhang, Ruifeng Shi, Zihe Zhang, Hongyu Liu, Jun Chen

Pre-ClinicalKirk SmithDecember 1, 2020EML4-ALK, JAK2-STAT pathway, transformation, NSCLC

ALK Rearrangement Adenocarcinoma with Histological Transformation to Squamous Cell Carcinoma Resistant to Alectinib and Ceritinib

Specific tyrosine-kinase inhibitors (TKIs) are widely used for the treatment of non-small-cell lung cancers with anaplastic lymphoma kinase (ALK) translocations. However, most treated patients eventually develop resistance to the TKIs. The histological transformation into small cell carcinoma is well known to be the underlying mechanism for acquired resistance; however, transformation to squamous cell carcinoma is extremely rare. We, herein, report a case of ALK rearrangement-positive adenocarcinoma that transformed to squamous cell carcinoma after administration of alectinib, and was found to be resistant to ceritinib. READ ARTICLE

OncoTargets and therapy DOI:10.2147/OTT.S236706

Authors: Kaiho T, Nakajima T, Iwasawa S, Yonemori Y, Yoshino I.

Case StudyKirk SmithFebruary 19, 2020lung adenocarcinoma, anaplastic lymphoma kinase, transformation, squamous cell carcinoma, acquired resistance